Quadria Capital raises $1.4b in oversubscribed fund III exercise

Proceeds will be invested in 10 market-leading companies.

Quadria Capital closed its fund III exercise with $1.4b (US$1.07b), surpassing its $1.02b (US$800m) target.

The oversubscribed fundraising comprises over $1.2b (US$954m) in primary commitments and $146m (US$114m) in committed co-investment capital.

An additional $385m (US$300m) co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately $1.66b (US$1.3b) upon full deployment.

Proceeds from the fund will be used to build a diversified portfolio of around 10 market-leading companies, taking both minority and majority stakes, and expanding impact through targeted co-investments from Limited Partners (LPs).

Currently, about 40% of the fund has been invested in Aragen Life Sciences, NephroPlus, and Maxivision.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia